Pb
Abscopal responses are not a circumstance confined to sometime in the future. The company has already achieved Abscopal effects in its research. Its not something buried deep in the fine print.
From here on, the process is about establishing clinical evidence regarding things like frequency, duration and extent of the Abscopal responses. That's my understanding anyway.
DARRT 1 trial protocols provided Veyonda with not much more than a mere jab in its arsenal. DARRT 2 evens up the fight against a killer that has been around for probably millenniums.
Based on the overall evidence thus far, in some instances Veyonda is clearly no underdog in relation to the current standard of care - or even perhaps in time, the Big C itself.
Radiotherapy Improvements ALLOWED, page-15
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |